Vyxeos for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cytarabine and daunorubicin given together in liposomes may have fewer side effects and work better than cytarabine and daunorubicin given alone in patients with acute myeloid leukemia.
Who Is on the Research Team?
Gregory K Behbehani, MD, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with acute myeloid leukemia who didn't respond to initial chemo. They must be fit enough for intensive treatment, have proper heart function and organ health, and not exceed a lifetime dose of certain chemo drugs. Participants need to use effective contraception and cannot be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants are monitored monthly for progression-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Liposome-encapsulated Daunorubicin-Cytarabine
Liposome-encapsulated Daunorubicin-Cytarabine is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University Comprehensive Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator